Notably, network pharmacology predicts that RRP’s components (e.g., baicalin) target phosphodiesterases (PDE4/5), which degrade cAMP/cGMP, suggesting that RRP may restore cyclic nucleotide homeostasis to alleviate BDS. This evidence concerns the gene PDE4A and Diamond-Blackfan anemia.